Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $4 | $49 |
| - Cash | $1 | $1 | $3 | $8 |
| + Debt | $46 | $43 | $71 | $116 |
| Enterprise Value | $46 | $43 | $72 | $157 |
| Revenue | $19 | $18 | $17 | $8 |
| % Growth | 6.3% | 8.2% | 104.2% | – |
| Gross Profit | $16 | $12 | $12 | $4 |
| % Margin | 80.2% | 64.3% | 73.8% | 50.8% |
| EBITDA | -$7 | -$16 | -$82 | -$166 |
| % Margin | -35.7% | -88.2% | -487.5% | -2,010.9% |
| Net Income | -$9 | $53 | -$77 | -$205 |
| % Margin | -45.8% | 290.8% | -455.5% | -2,489% |
| EPS Diluted | -0.092 | 0.051 | -164.59 | -2,962.49 |
| % Growth | -280.9% | 100% | 94.4% | – |
| Operating Cash Flow | -$4 | -$9 | -$70 | -$147 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$3 |
| Free Cash Flow | -$4 | -$9 | -$71 | -$150 |